Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.36 |
| ▸ | CTSD | P07339 | 12/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981358 | 0.99 | OPRL1 (0.35) | BACE1CTSDOPRL1MAPTALDH1A1 | |
| SCHEMBL4192601 | 0.88 | CTSD (0.37) | BACE1CTSDOPRL1CYP3A4 | |
| SCHEMBL979358 | 0.84 | CACNA1B (0.32) | BACE1CTSDOPRL1ALDH1A1 | |
| SCHEMBL977080 | 0.80 | BACE1 (0.35) | BACE1CTSD | |
| SCHEMBL979457 | 0.78 | BACE1 (0.33) | BACE1CTSDOPRL1 | |
| SCHEMBL1225572 | 0.73 | DGAT2 (0.35) | OPRL1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL12788407 | 0.72 | MAPT (0.41) | MAPTALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL12950960 | 0.71 | TSHR (0.35) | BACE1CTSDMAPT | |
| SCHEMBL13502665 | 0.69 | MAPT (0.42) | MAPTALDH1A1L3MBTL1 | |
| SCHEMBL1013637 | 0.69 | RIPK1 (0.34) | BACE1CTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029575-B1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8765759-B2 | Monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2271346-B1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7893079-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2271346-A2 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100056498-A1 | SUBSTITUTED MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| US-7629338-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7625901-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2009120652-A2 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-2029575-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
| WO-2008020902-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | CCKAR, CALCRL, CCKBR | BACE1 1154/4885CTSD 1652/4885OPRL1 31/4885 |
| US-20100056498-A1 | SUBSTITUTED MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | QRFPR, CALCRL, EDNRB | BACE1 1063/4885CTSD 2087/4885OPRL1 18/4885 |
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | CALCRL, CALCR, GRPR | BACE1 1229/4885CTSD 892/4885OPRL1 4/4885 |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | EDNRB, CALCRL, QRFPR | BACE1 1089/4885CTSD 2124/4885OPRL1 19/4885 |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | QRFPR, CALCRL, EDNRB | BACE1 1063/4885CTSD 2087/4885OPRL1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.